NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) is a clinical-stage biopharmaceutical company focused on creating novel therapeutics that use molecules to treat medical conditions with no approved cure. The Company’s lead product candidate is ZYESAMI™ (AVIPTADIL®) ZYESAMI™ (Aviptadil acetate), a synthetic Vasoactive Intestinal Peptide (VIP), which has...
Insider selling cannot be the sole indicator for investing in a stock, but it would be wise to make a note of the buying and selling activities to gauge a company’s prospects or the lack thereof. While insiders buying or selling the Company’s stock could...
Insider selling cannot be the sole indicator for investing in a stock, but it would be wise to make a note of the buying and selling activities to gauge a company’s prospects or the lack thereof. While insiders buying or selling the Company’s stock could...
Scopus BioPharma, Inc. (NASDAQ: SCPS), a biopharmaceutical company, announced the approval of an investigational drug application (IND) for CpG-STAT3siRNA, an immuno-oncology RNA therapy intended for the treatment of multiple cancers. CpG-STAT3siRNA, or CO-sTiRNA™, the company’s lead product candidate is a first-in-class, targeted immuno-oncology gene therapy and...
